

Datasheet for ABIN94381

anti-HLAG antibody (C-Term) (Biotin)





	ve	rvi	0	W
\circ	v C	1 V I	\sim	v v

Specificity:

Cross-Reactivity (Details):

Quantity:	0.1 mg		
Target:	HLAG		
Binding Specificity:	C-Term		
Reactivity:	Human		
Host:	Mouse		
Clonality:	Monoclonal		
Conjugate:	This HLAG antibody is conjugated to Biotin		
Application:	Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunohistochemistry (Frozen		
	Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)),		
	Immunocytochemistry (ICC)		
Product Details			
Immunogen:	C-terminal amino acid sequence (22-mer) of soluble HLA-G5 and HLA-G6 proteins coupled to		
	ovalbumin.		
Clone:	5A6G7		
Isotype:	lgG1		

HLA-G1.

Human

The mouse monoclonal antibody 5A6G7 was generated to a peptide corresponding to C-intron

4-encoded sequence. This antibody does not crossreact with the full-length HLA-G1 isoform and thus allows to distinguish between secreted HLA-G5 and HLA-G6 isoforms from shedded

Product Details

Purification:

Purified antibody is conjugated with biotin LC-NHS ester under optimum conditions and unconjugated antibody and free biotin are removed by size-exclusion chromatography.

Target Details

Target: HLAG

Alternative Name: HLA-G (HLAG Products)

Background:

Major histocompatibility complex, class I, G, Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.

Gene ID:

3135

UniProt:

P17693

Pathways:

Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response

Application Details

Application Notes:	Flow cytometry: Recommended dilution: 1-4 µg/mL. Intracellular staining.		
Comment:	The purified antibody is conjugated with Biotin-LC-NHS under optimum conditions. The reagent		
	is free of unconjugated biotin.		
Restrictions:	For Research Use only		
I I a sa allisa as			
Handling			
Concentration:	1 mg/mL		
Buffer:	Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide		
Preservative:	Sodium azide		
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which		
	should be handled by trained staff only.		
Handling Advice:	Do not freeze.		
	Avoid prolonged exposure to light.		
Storage:	4 °C		
Storage Comment:	Store at 2-8°C. Do not freeze.		
Publications			
Product cited in:	Poláková, Železníková, Russ: "HLA-G5 in the blood of leukemia patients and healthy individuals."		
	in: Leukemia research , Vol. 37, Issue 2, pp. 139-45, (2013) (PubMed).		
	Later Drohoud Magret Latera Mauillet Dog Marcou Dougs Freige Carocolle: "Modulation of		
	Lafon, Prehaud, Megret, Lafage, Mouillot, Roa, Moreau, Rouas-Freiss, Carosella: "Modulation of HLA-G expression in human neural cells after neurotropic viral infections." in: Journal of		
	virology , Vol. 79, Issue 24, pp. 15226-37, (2005) (PubMed).		
	2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2		
	Le Rond, Gonzalez, Gonzalez, Carosella, Rouas-Freiss: "Indoleamine 2,3 dioxygenase and		


Rebmann, Lemaoult, Rouas-Freiss, Carosella, Grosse-Wilde: "Report of the Wet Workshop for Quantification of Soluble HLA-G in Essen, 2004." in: **Human immunology**, Vol. 66, Issue 8, pp. 853-63, (2005) (PubMed).

human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent

pathways." in: Immunology, Vol. 116, Issue 3, pp. 297-307, (2005) (PubMed).


Le Rond, Le Maoult, Créput, Menier, Deschamps, Le Friec, Amiot, Durrbach, Dausset, Carosella, Rouas-Freiss: "Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients." in: **European journal of immunology**, Vol. 34, Issue 3, pp. 649-60, (2004) (PubMed).

Images



Flow Cytometry

Image 1. Flow cytometry analysis (intracellular staining) of HLA-G in HLA-G1 transfectants with anti-HLA-G (5A6G7) biotin / streptavidin-APC.



Western Blotting

Image 2. Western Blotting analysis of whole cell lysate of HLA-G stable transfectants (various splice variants) using anti-human HLA-G (5A6G7). Lane 1: M8 cell line transfected with empty vector Lane 2: M8 cell line transfected with HLA-G1 Lane 3: M8 cell line transfected with HLA-G5 Lane 4: M8 cell line transfected with HLA-G6